Alkermes (ALKS) Competitors

$24.15
-0.31 (-1.27%)
(As of 05/17/2024 ET)

ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, LGND, DVAX, PCRX, MNKD, and IRWD

Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), MannKind (MNKD), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.

Alkermes vs.

Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.9% of Alkermes shares are owned by company insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alkermes has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.

Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.66B2.46$355.76M$2.539.55
Madrigal PharmaceuticalsN/AN/A-$373.63M-$23.09-9.53

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Alkermes. MarketBeat recorded 12 mentions for Madrigal Pharmaceuticals and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.21 beat Madrigal Pharmaceuticals' score of -0.31 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alkermes received 235 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 68.60% of users gave Madrigal Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
AlkermesOutperform Votes
685
70.69%
Underperform Votes
284
29.31%
Madrigal PharmaceuticalsOutperform Votes
450
68.60%
Underperform Votes
206
31.40%

Alkermes has a net margin of 25.17% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 20.31% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes25.17% 20.31% 11.85%
Madrigal Pharmaceuticals N/A -128.60%-78.52%

Alkermes presently has a consensus target price of $35.38, indicating a potential upside of 46.48%. Madrigal Pharmaceuticals has a consensus target price of $345.09, indicating a potential upside of 56.82%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Madrigal Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

Summary

Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.09B$6.75B$5.31B$7.96B
Dividend YieldN/A2.61%43.94%3.91%
P/E Ratio9.5522.54151.2918.78
Price / Sales2.46251.742,358.5377.92
Price / Cash10.7836.4736.7331.98
Price / Book3.265.905.744.76
Net Income$355.76M$131.19M$106.98M$217.17M
7 Day Performance0.42%1.47%1.41%2.90%
1 Month Performance1.26%4.80%4.94%6.66%
1 Year Performance-20.77%-3.61%7.83%9.89%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
4.4648 of 5 stars
$210.98
-0.2%
$345.09
+63.6%
-20.4%$4.50BN/A-9.14376Insider Selling
Gap Down
FOLD
Amicus Therapeutics
4.3994 of 5 stars
$9.33
+3.2%
$18.40
+97.2%
-16.9%$2.76B$399.36M-19.04517Analyst Upgrade
Short Interest ↓
IONS
Ionis Pharmaceuticals
4.6622 of 5 stars
$38.27
-1.4%
$59.54
+55.6%
+1.9%$5.59B$788M-14.33927Short Interest ↓
News Coverage
GERN
Geron
3.6447 of 5 stars
$3.68
-1.6%
$6.10
+65.8%
+27.9%$2.18B$240,000.00-10.51141
AGIO
Agios Pharmaceuticals
1.3838 of 5 stars
$34.14
+1.8%
$35.00
+2.5%
+33.0%$1.94B$26.82M-5.40383
LGND
Ligand Pharmaceuticals
4.9103 of 5 stars
$85.29
+1.5%
$116.33
+36.4%
+11.9%$1.54B$131.31M16.5058Insider Selling
News Coverage
DVAX
Dynavax Technologies
4.3367 of 5 stars
$11.00
-0.3%
$25.33
+130.3%
+1.4%$1.44B$232.28M183.33408Short Interest ↑
Analyst Revision
PCRX
Pacira BioSciences
4.929 of 5 stars
$30.82
+1.4%
$47.40
+53.8%
-23.5%$1.43B$681.75M21.55711
MNKD
MannKind
3.0951 of 5 stars
$4.50
+2.0%
$8.00
+77.8%
+0.7%$1.23B$224.60M150.05411
IRWD
Ironwood Pharmaceuticals
4.3585 of 5 stars
$6.63
-0.9%
$18.40
+177.5%
-36.6%$1.04B$413.55M-0.98267Short Interest ↓

Related Companies and Tools

This page (NASDAQ:ALKS) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners